illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. BioKangtai
Company logo

BioKangtai | Sustainability Performance

https://www.biokangtai.com/
Linkedin

Develops and manufactures biological products and vaccines. Operations include research, production, and distribution of pharmaceuticals for immunization, diagnostics, and treatment purposes, with compliance to regulatory standards and quality assurance processes.

1992

China

1,001 - 5,000 employees

Biotechnology

$100M - 500M in revenue

$10M - 25M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#11656
Overall
#744
in China
#235
in Biotechnology

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Governance
TargetsESG scores and exclusionsB-corp & CDP
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Shandong Buchang Pharmaceuticals

China, Hospital & Health Care, Pharmaceuticals


Company logo
INT Medical Instruments

China, Hospital & Health Care, Medical Device


Company logo
Shanghai Fudan Zhangjiang Bio Pharmaceutical

China, Hospital & Health Care, Pharmaceuticals

Market cap

98.3B $, 2026▼46.3% YoY

Revenue

374.9M $, 2025▲0.8% YoY

R&D intensity

20.31% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

98.3B $, 2026▼46.3% YoY

Revenue

374.9M $, FY2025▲0.8% YoY

EBITDA

12.1M $, FY2025▼9.1% YoY

Operating margin

3% Industry: -370▼110.1% YoY

Revenue & EBITDA

$374.9MFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

18.4M 2024▼140.1% YoY

Capex

66.2M 2024▼52.1% YoY

Debt/equity ratio

0.2 Industry: 2▼NaN% YoY

R&D intensity

20.3%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

1.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.5

▼ 8.6%

2023

0.4

▼ 12.8%

2024

0.4

▼ 5.9%

2025

3.2

2028

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Available

Recycling policy

Not available

Workplace health & safety policy

Available

23%
Independent Directors

3 out of 13 incl. management

Powered by illuminem

Overall score

59

Environment

59

Social

78

Governance

39

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

CDP Scores


Climate Score

Not disclosed

Water Score

Not disclosed

A

A-

B

B-

C

C-

D

D-

Powered by illuminem and GIST impact

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


    Available in
    Scale package

    Access
  • Email

  • Email